Biomunex Pharmaceuticals announces the start of a Phase 1 clinical trial for its first-in-class bispecific antibody for the treatment of cancer

Biomunex Pharmaceuticals announces the start of a Phase 1 clinical trial for its first-in-class bispecific antibody for the treatment of cancer

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,France ,French ,Pierre Emmanuel Gerard ,Simon Plyte ,Biomunex Pharmaceuticals ,Onward Therapeutics ,Chief Scientific Officer ,About Biomunex Pharmaceuticals ,